… ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that clinical study PQ-010-002, a proof-of-concept study of nasal … well-tolerated in both cohorts. ProQR also announced that clinical study PQ-010-001 completed all four single-dose … used as an important endpoint to assess CFTR function in clinical trials in CF. As CFTR dysfunction is the key problem …
… we have made a lot of progress towards initiating our clinical studies for QR-010 in patients with cystic fibrosis … In the first half of 2016 we intend to start our first clinicaltrial for QR-110 in patients suffering from the most common …
… of 2016. “We continue to make great progress with our clinical development programs. Our first molecule, QR-010 for cystic fibrosis is in two active clinical trials and our second molecule, QR-110 for LCA10 is … The increase in expenses was primarily due to the clinicaltrial costs for QR-010 and clinic enabling studies for …
… our balance sheet, which will allow us to advance the clinical development of QR-010 for the treatment of patients … of CF key opinion leaders, as well as to an extensive clinicaltrial network infrastructure. Successfully completed our …
… today announced that the company will present pre-clinical data for QR-010 at the 39 th European Cystic … lead molecule, is currently being studied in two active clinical trials in patients with cystic fibrosis associated …
… three-month interim analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and … there are no pharmaceutical treatments approved or in clinical development that treat the vision loss associated … announcement of interim analysis findings from our QR-421a clinicaltrial and the therapeutic potential of our product …
… the results in detail. About the PQ-110-001 Phase 1/2 trial PQ-110-001 is a first-in-human open-label trial that … our announcement of top-line results from our PQ-110-001 clinicaltrial and the therapeutic potential of our product …